Archives
-
Pitavastatin (NK-104): In Vitro Workflow Guide
2026-09-19
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for in vitro studies of cholesterol biosynthesis and related cellular readouts. This guide covers formulation, controls, QC, and interpretation limits; it is not a validated clinical, therapeutic, or in vivo animal-dosing protocol.
-
Alosetron in 5-HT3 Gut Signaling Research
2026-09-18
Alosetron enables controlled interrogation of 5-HT3 receptor biology in epithelial, motility, and visceral pain models. This workflow pairs receptor antagonism with CDC42–YAP–Ereg–mTOR readouts to distinguish established polarity mechanisms from testable serotonin-linked hypotheses.
-
GSK 2837808A: Reliable LDHA Assay Design
2026-09-18
A scenario-based guide to using GSK 2837808A (SKU B4929) for reproducible LDHA, lactate, glucose-consumption, and viability studies. It separates validated hepatocellular carcinoma evidence from exploratory colorectal cancer applications and provides practical formulation, interpretation, and vendor-selection guidance.
-
MRTFA-KCNMB1 Axis in Cancer Cell Stiffness
2026-09-17
The reference study identifies potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. By combining mechanical measurements, electrophysiology, immune-cell killing assays, transcriptomics, and mouse models, the authors show that BK-channel activation can stiffen cancer cells, improve immune-mediated lysis, and reduce metastatic colonization.
-
GW4064: FXR Agonist Workflow for Fibrosis Studies
2026-09-17
GW4064 provides a receptor-focused way to connect FXR activation with lipid metabolism, inflammatory signaling, ferroptosis, and collagen deposition. This workflow translates recent LX-2 cell findings into practical assay design, formulation controls, and troubleshooting steps for metabolic and fibrosis research.
-
Doxycycline hyclate for MMP and BBB Research
2026-09-16
Doxycycline hyclate provides a practical pharmacological route for testing how MMP-2 and MMP-9 contribute to blood–brain barrier failure, neuronal apoptosis, and cognitive injury. This workflow translates a mouse arsenic-exposure model into reproducible formulation, assay, dosing, and troubleshooting decisions while distinguishing validated findings from exploratory applications.
-
Ertapenem in Carbapenem Resistance Research
2026-09-16
A mechanistic and translational guide to using Ertapenem sodium salt for phenotype–genotype studies of carbapenemase-mediated resistance and plasmid transmission.
-
α-Bungarotoxin for Reliable Receptor Blockade
2026-09-15
This scenario-driven guide explains how α-Bungarotoxin, SKU B6950, can strengthen mechanistic interpretation in viability, proliferation, cytotoxicity, and cholinergic signaling assays. It combines receptor pharmacology, practical handling, vendor-selection criteria, and evidence from a placental necroptosis model.
-
Live-Dead Cell Staining Kit for Biomaterial Decisions
2026-09-15
The Live-Dead Cell Staining Kit uses Calcein-AM and Propidium Iodide to distinguish viable from membrane-compromised cells. This guide explains how to interpret the assay in biomaterial cytocompatibility studies, with particular insight from a multifunctional hemostatic adhesive study.
-
Caffeine as a Translational Research Strategy
2026-09-14
Caffeine is more than a familiar bioactive molecule: it is a mechanistically informative perturbation tool for cancer, metabolism, and neurobiology. This article places 1,3,7-trimethylpurine-2,6-dione within a target-aware translational framework, using recent ALDH2 activator research to clarify assay design, competitive positioning, and responsible interpretation.
-
GSK J4 HCl: Decoding H3K27 Biology
2026-09-14
Explore how GSK J4 HCl, a cell-permeable JMJD3 inhibitor, can clarify H3K27-dependent transcription and inflammatory signaling. This article connects product pharmacology with the hCG–CXCL10 decidual model to improve assay interpretation and experimental design.
-
GSK J4 HCl: Reliable JMJD3 Assay Design
2026-09-13
Learn how GSK J4 HCl (SKU A4190) can be incorporated into cell viability, inflammatory, proliferation, and epigenetic workflows without confusing metabolic readouts with cell number. This scenario-based guide covers mechanism, controls, dosing interpretation, formulation, and practical supplier selection.
-
Patient-Derived 3D Spheroids for Prostate Cancer
2026-09-12
Linxweiler and colleagues developed viable three-dimensional spheroid cultures directly from radical prostatectomy specimens, creating a translational model for organ-confined prostate cancer. The cultures retained key prostate epithelial and tumor markers, could be cryopreserved, and showed differential responses to androgen receptor-directed drugs, although their drug-response results require careful interpretation outside the ex vivo setting.
-
Dual HER2–VEGFR-2 Targeting in TNBC
2026-09-11
The 2026 reference study evaluates Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is phenotype-first evidence linking treatment with reduced invadopodia formation, proliferation, and two-dimensional tube formation, while also exposing the difficulty of assigning target-specific mechanisms in receptor-negative models.
-
Doxorubicin Beyond the Benchmark
2026-09-11
Doxorubicin remains a foundational DNA-damage tool, but its greatest translational value emerges when researchers connect mechanism, model selection, senescence biology, and assay strategy without confusing adjacent evidence with direct validation.